Last reviewed · How we verify
Vonoprazan and Amoxicillin
Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis.
Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria by disrupting cell wall synthesis. Used for Helicobacter pylori infection eradication (as part of combination therapy).
At a glance
| Generic name | Vonoprazan and Amoxicillin |
|---|---|
| Sponsor | Kaohsiung Medical University |
| Drug class | Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) |
| Target | H+/K+-ATPase (vonoprazan); bacterial cell wall peptidoglycan (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a combination therapy for H. pylori eradication. Vonoprazan (a potassium-competitive acid blocker) suppresses gastric acid production, creating an environment where amoxicillin can more effectively penetrate and eliminate H. pylori. Amoxicillin works by inhibiting bacterial cell wall cross-linking, leading to bacterial cell death. Together, they form part of a triple or quadruple therapy regimen for H. pylori infection.
Approved indications
- Helicobacter pylori infection eradication (as part of combination therapy)
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Allergic reaction (amoxicillin)
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection (PHASE2)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy (NA)
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori (NA)
- Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy, Vonoprazan-amoxicillin Dual Therapy and Proton Pump Inhibitor-based Standard Triple Therapy for Hp Eradication (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan and Amoxicillin CI brief — competitive landscape report
- Vonoprazan and Amoxicillin updates RSS · CI watch RSS
- Kaohsiung Medical University portfolio CI